Company: BIAF
Filing Date: 2025-03-07
Form Type: 8-K
Source: 0001493152-25-009452
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-07
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item
7.01. Regulation FD Disclosure.

On
March 6, 2025, bioAffinity Technologies, Inc. (the “ Company”) issued a press release announcing that it was implementing
targeted actions to deliver approximately $4.0 million in cost savings at its subsidiary, Precision Pathology Laboratory Services (“ PPLS”),
while increasing resources that support continued sales growth for CyPath® Lung, the Company’s noninvasive test for early-stage
lung cancer.

The
Company expects to achieve the majority of the cost savings on an annual run-rate through: (i) decreased labor cost reductions, including
an approximately 38% workforce reduction at PPLS; (ii) operational efficiency enhancements, such as reduced direct costs for purchased
services and supplies; and (iii) a focus on high-margin services by discontinuing certain pathology services with suboptimal profit margins.

The
information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference
into any filing with the U. S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K
includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating
that certain statements contained therein are “forward-looking” rather than historical.